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Gamma-secretase is involved in the production of Aβ amyloid peptides. It cleaves the transmembrane domain of the amyloid
precursor protein (APP) at alternative sites to produce Aβ and the APP intracellular domain (AICD).Metal ions play an important
role in Aβ aggregation and metabolism, thus metal chelators and ligands represent potential therapeutic agents for AD treatment.
A direct eﬀe c to fm e t a lc h e l a t o r so nγ-secretase has not yet been investigated. The authors used an in vitro γ-secretase assay
consisting of cleavage of APP C100-3XFLAG by endogenous γ-secretase from rodent brains and human neuroblastoma SH-SY5Y,
and detected AICD production by western blotting. Adding metalloprotease inhibitors to the reaction showed that clioquinol,
phosphoramidon,andzincmetalloproteaseinhibitorshadnosigniﬁcanteﬀectonγ-secretaseactivity.Incontrast,phenanthroline,
EDTA, and EGTA markedly decreased γ-secretase activity that could be restored by adding back calcium and magnesium ions.
Mg2+ stabilized a 1,000kDa presenilin 1 complex through blue native gel electrophoresis and size-exclusion chromatography. Data
s u g g e s tt h a tC a 2+ and Mg2+ stabilize γ-secretase and enhance its activity.
1.Introduction
Gamma-secretase is a key protease activity involved in the
production of Alzheimer’s disease Aβ amyloid peptides
and in regulated intramembrane processing of a subset of
membrane receptors, including Notch (reviewed in [1]). Aβ
is proteolytically derived from the type I integral amyloid
precursor protein (APP) [2] by two sequential cleavages.
Shedding of the large APP ectodomain by β-secretase (β-
APP cleaving enzyme1, BACE1) [3] produces a 99 amino
acid membrane-tethered stub (β-secretase generated APP C-
terminal fragment, βCTF, or C99) that is further processed
by γ-secretase to liberate Aβ peptides in the extracellu-
lar/luminal space. γ-Secretase cleaves the transmembrane
domain of APP at multiple sites. Cleavage at the ε-site [4], at
position 49-50 according to numbering from Aβ N-terminus
mediates the cytosolic release of APP intracellular domain
(AICD) together with its binding partners and regulates
their nuclear translocation [5]. Further cleavages at the
ζ/(46-47) and γ/(40-41) sites generate Aβ40 [6]. Pathogenic
mutations in APP or in the presenilins result in shifting
of ε-cleavage to the (48-49) site and production of Aβ42
[7]. APP also undergoes ectodomain shedding by cleavage
within the Aβ domain by α-secretase, in a nonamyloidogenic
cellular pathway, followed by γ-secretase processing of the
corresponding membrane stub (C83) to release AICD and
ap 3f r a g m e n t( r e v i e w e di n[ 8]).
γ-Secretase activity is contained within high molecular
complexes formed by assembly of four integral membrane
proteins, presenilin, nicastrin, Aph-1, and Pen-2 [9]. Gene
knockout experiments [10] and mutation of two con-
served aspartates [11] have revealed that the presenilins,2 International Journal of Alzheimer’s Disease
either PS1 or PS2, are membrane proteases and constitute
the catalytic subunits of γ-secretase complexes.
The mechanism of γ-secretase and its modulation are
yet to be elucidated. We aimed to investigate the eﬀect
of metal chelators on γ-secretase activity in vitro. Indeed,
biometals and metalloenzymes play an important role in
the metabolism of APP and Aβ. APP itself comprises two
zinc/copper binding sites, one of them located within the
Aβ sequence [12–14]. Although the precise function of APP
remains unclear, a wealth of experimental evidence indicates
that it plays a role in copper homeostasis [15]. The reduction
of Cu2+ to Cu+ by APP is accompanied by the production
of hydrogen peroxide resulting in oxidative stress [16]. Also,
metal ions, particularly copper, mediate Aβ oligomerization
and toxicity [17], therefore metal chelators and ionophores
are currently being evaluated as drug candidates for AD
treatment (reviewed in [18]). To support the merit of this
therapeutic approach, the copper chelator clioquinol (CQ)
has been shown to reduce Aβ deposition in the brain of an
AD transgenic mouse model [19].
Metals are also implicated in Aβ clearance as the
enzymes that metabolize Aβ peptides are zinc-dependent
(for a complete review, see [20]), in particular the insulin-
degrading enzyme (IDE) [21–24], neprilysin (NEP) [25–
27], and the matrix-metalloproteinases MMP2 and MMP9
[28–30]. Secretase processing of APP is also inﬂuenced by
metalions since the α-secretaseenzymes belong to thefamily
of ADAM proteases, which are zinc-metalloproteases [31],
and the β-secretase enzyme; BACE1 comprises a copper-
binding site within its cytoplasmic tail, which may regulate
its enzymatic activity [32].
Inthis paper,wehaveevaluatedthedirect eﬀectsofmetal
chelatorsonγ-secretaseinaninvitroassayusingendogenous
enzymeextractedfromguineapigandmousebrains,orfrom
human neuroblastoma SH-SY5Y cells, together with C100-
3XFLAG substrate, an analogue of APP β-CTF.
2.MaterialsandMethods
2.1. Materials and Reagents. Adenosine 5 -triphosphate
disodiumsalt(ATP),ethyleneglycol-bis[2-aminoethylether]-
N,N,N ,N -tetraacetic acid (EGTA), glycerol, 5-chloro7-iodo
-8-hydroxyquinoline (clioquinol or CQ), D,L-thiorphan, P-
2714 protease inhibitor cocktail, [3-[(3-cholamidopro-
pyl)dimethylammonio-]-2-hydroxy-1-propanesulfonate]
(CHAPSO), M2 monoclonal antibody, and anti-FLAG M2-
agarose were purchased from Sigma-Aldrich (Sydney,
Australia).Glycerol,phosphoramidonand1,10-phenanthro-
line were from Merck Biosciences (Victoria, Australia).
GM6001(ilomastat)wasobtainedfromChemicon(Boronia,
Victoria, Australia). L-685,458 inhibitor was obtained from
Dr. Mark Shearman (Merck, Sharpe, and Dohme).
2.2. C100-3XFLAG Preparation and Puriﬁcation. E. Coli
transformed with the C100-3XFLAG vector were grown
and induced for C100-3XFLAG expression as described
before [33]. The cells were harvested, resuspended in 50mM
HEPES, 5mM MgCl2,5m MC a C l 2, 150mM KCl, and pH
7.4, supplemented with 1% (w/v) P-2714 (Sigma) protease
inhibitor cocktail, and disrupted by sonication. Membranes
were isolated by centrifugation for 1 hour at 100,000g,
and were resuspended in homogenisation buﬀer containing
1% (v/v) CHAPSO, using a Dounce homogenizer, followed
by repeated passages through syringe needles of decreasing
bore size. The resultant ﬁne suspension was incubated for 1
hour at 4◦C, with end-over-end rocking, then centrifuged at
18,000g for 1 hour at 4◦C, and the supernatant containing
the solubilized proteins was brought up to 10% glycerol
(v/v). C100-3FLAG was aﬃnity-puriﬁed on anti-FLAG M2-
agarose column and the puriﬁed substrate was stored as
aliquots at −80◦C.
2.3. Preparation of γ-Secretase Activity. All steps were carried
out on ice and the centrifugation steps done at 4◦C. Guinea
pigs and mouse (C57/Bl6) brains were obtained from the
Animal Facility of the University of Melbourne Department
of Pathology as secondary tissue usage of excess animals.
Homogenates from whole brains, minus cerebellum, were
prepared as described previously [33]. The crude tissue
homogenate prepared in 20mM HEPES, pH 7.4, containing
250mM sucrose, and 1% protease inhibitor cocktail (with
no pepstatin), was centrifuged at 3,000g for 30minutes to
remove cellular debris. The supernatant was collected and
centrifuged further at 100,000g for 1 hour in a L8-80M
ultracentrifuge equipped with a Ti70.1 rotor (Beckman-
Coulter). The pellet was washed with 20mM HEPES,
150mMKCl,andpH7.4,andresuspendedinthesamebuﬀer
plus 1% (v/v) CHAPSO, with mixing on a rotating platform
for 1 hour, at 4◦C. CHAPSO-extracted membranes were
removed by centrifugation at 18,000g for 20 minutes The
supernatant, containing solubilized γ-secretase, was brought
up to 10% glycerol (v/v), and stored as aliquots at −80◦C.
Alternatively, SH-SY5Y cells were resuspended in 20mM
HEPES, 80mM KCl, and pH 7.3, supplemented with 1%
protease inhibitor cocktail, and homogenized by repeated
passages through a 25-gauge needle. The cell homogenate
was centrifuged at 1,000g for 20min to remove nuclei and
cell debris. The resultant supernatant was collected and
centrifuged for 1 hour at 100,000g. The sediment pellet was
extracted with 1% CHAPSO.
2.4. Gamma-Secretase Assays. Puriﬁed recombinant sub-
strate(∼1.5μM)andCHAPSO-solubilizedmembranes(5μg
of guinea pig or mouse brain preparation, or 15μgo f
SH-SY5Y membrane extract) were incubated for 4 to
18 hours at 37◦Ci np r e s e n c eo fA T P( 1 . 2 5 m M )a n da
mixture of phosphotidyl-ethanolamine (PE) and phospho-
tidylcholine (PC) (50ng each; Sigma-Aldrich) in a ﬁnal
reaction volume of 20μLo f2 0 m MH E P E S( p H7 . 4 )a n d
0.5% CHAPSO, plus either 2mM EDTA (buﬀer E) or
5mM CaCl 2,5 m MM g C l 2 and 150mM KCl (buﬀer A).
Inhibitors were prepared as stocks in DMSO and used at
dilutions so that DMSO concentration in incubations was
no more than 2.5%. Incubations were terminated by adding
Laemmli SDS sample buﬀer and heating at 95◦Cf o r5
minutes. The samples were electrophoresed for 5 hours onInternational Journal of Alzheimer’s Disease 3
Tris-tricine gels (two-layer, 10–15% acrylamide discontinu-
ous gradient) using a miniPROTEAN 3 system (Bio-Rad)
followedbyelectrotransfertonitrocellulose(Trans-blot,Bio-
Rad). The blots were boiled in phosphate buﬀer saline, pH
7.4 (PBS) for 3min prior to blocking for 1 hour with 0.5%
casein in PBS and probing with primary antibody for 2
hours. The blots were developed with the Super Signal West
Dura kit (Pierce, Rockford, Il) and exposed to a GeneGnome
digitalimagingsystem(Syngene,Cambridge,UK).Datawere
analysed using GeneTools software (Syngene). γ-Secretase
activity was expressed as the ratio of AICD signal to the
sum of C100 plus AICD signals after subtracting blank
values. Aβ was quantiﬁed by DELFIA as described before
[34]. In brief, plates were coated with mouse monoclonal
antibody G210 (speciﬁc for Aβ40) and developed with
biotinylated WO2 (anti-Aβ 1–16). Bound antibody was
detected with streptavidin-labeled Europium (Perkin Elmer,
Inc, Melbourne, Victoria). Results were calculated from a
standard curve obtained with Aβ40 synthetic peptide.
2.5. BN-PAGE Analysis. SH-SY5Y membrane extract (0.5%
CHAPSO), prepared as described above, was mixed with an
equal volume of 20mM HEPES (pH 7.4) containing 0.5%
CHAPSO plus one of the following, 2mM EDTA, 2mM
EGTA, 5mM MgCl2,o r5 m MC a C l 2, and incubated for
1 8h o u r sa t1 9 ◦C. BN-PAGE sample buﬀer was added and
the samples resolved on 3–8% NuPAGE Tris-acetate gels
(Invitrogen) as described previously [35].
2.6. Size-Exclusion Chromatography. SH-SY5Y membrane
extracts (diluted to 0.5% CHAPSO) prepared as for BN-
PAGE were fractionated on a Superose-6 column (GE
Healthcare) equilibrated in 20mM HEPES, 150mM KCl
buﬀer, and pH 7.3 and eluted at a ﬂow rate of 0.5mL/min.
0.5mL fractions were collected and analysed by western
blotting with 98/1 antibody [36].
3. Results
3.1. In Vitro γ-Secretase Assay. C100 substrate, expressed in
E. coli, is based on the human APP C-terminal sequence,
which corresponds to the C-terminal fragment produced
by β-secretase cleavage of APP (β-CTF, the direct precursor
to Aβ) plus N-terminal Met596. C100 is expressed with a
3XFLAG C-terminal tag to improve solubility, stability, and
detection of AICD [33]. Incubations of C100-3XFLAG with
γ-secretase preparations from guinea pig brain membranes
produced a 10kDa C-terminal fragment that was inhibited
in a dose-response manner by two speciﬁc γ-secretase
inhibitors, L-685,458 [37], and DAPT [38] (Figure 1(a)).
AICD production was time dependent (Figure 1(b)). Detec-
tionofAβwithWO2showsanincreasedproductionbetween
2 and 4 hours but the results could not be quantiﬁed due
to high background and merging of the bands between the
lanes.
The eﬀects of phospholipids and ATP were tested to
further validate the AICD detection assay and optimize
conditions. Adding phospholipids (PC and PE, 2.5μg/mL
each) enhanced the production of AICD (Figure 1(c)), a
result consistent with reports by others [39, 40]. Adding
ATP (1.25mM) to the γ-secretase/APP substrate reaction
was also found to cause an average 1.6-fold increase of
AICD production (Figures 1(d) and 1(e)), corroborating
the report by Fraering et al. [41] who used recombinant γ-
secretase solubilized from membranes of cells overexpressing
the γ-secretase components. The positive eﬀect of ATP was
also obtained using γ-secretase preparations from SH-SY5Y-
membranes (data not shown).
3.2. Eﬀect of Zinc and Copper Chelators on γ-Secretase
Activity. The eﬀect of metal ion chelators and metallopro-
tease inhibitors on γ-secretase was evaluated using various
compounds (Figures 2(a) and 2(b)). The zinc chelators,
thiorphan and phosphoramidon, and the hydroxamate
inhibitor ilomastat, which is an inhibitor of α-secretase,
were all assayed at 250nM, a concentration suﬃcient to
completely inhibit their target metalloprotease activities in
cells and tissues. There was no signiﬁcant eﬀect of these
compounds in the γ-secretase assay, although thiorphan
showed a trend for an increase in AICD signal. Thiorphan
is an inhibitor of neprilysin, which might be present in
the assay as it is associated with brain membranes. The
modest decrease in γ-secretase activity in the presence of the
copper chelator clioquinol was not statistically signiﬁcant. In
contrast a 65% decrease in AICD production (P = .024;
N = 3) was observed in the presence of phenanthroline
(5mM),suggestingthatsomemetalionsfacilitateγ-secretase
activity.
3.3. Metal Chelators of Broad Speciﬁcity Decrease γ-Secretase
Activity. Thereductionofactivityinthepresenceofphenan-
throline led us to test the eﬀect of EDTA, another chelator
of broad speciﬁcity. Indeed, reports in the literature indicate
the use of alternative buﬀers for in vitro γ-secretase assays.
Notably, these involve the use of buﬀers that either contain
EDTA[41,42],orthataresupplementedwithCa2+ andMg2+
[39, 40, 43–45]. Therefore, we compared both conditions in
our assay (Figures 3(a) and 3(b)). In the presence of EDTA,
AICD production was 28% of that in the presence of buﬀer
with Ca2+ and Mg2+ (P = .0002, N = 5). Measurement
of Aβ40 production by a sandwich ELISA (Figure 3(c))
showed that 0.035 ± 0.01ng/mL Aβ40 was produced in the
presence of Ca2+ and Mg2+ whereas 0.011 ± 0.004ng/mL
was produced in the presence of EDTA, further supporting
that Ca2+ and Mg2+ ions facilitate the processing of C100
by γ-secretase. Similar results were obtained when using
solubilisedSH-SY5Ymembranesasthesourceofγ-secretase,
with AICD production in the presence of EDTA being 30%
to that in the presence of Ca2+ and Mg2+ (Figures 3(d)
and 3(e)). Comparing incubations with and without Ca2+
and Mg2+ showed that the addition of these metal ions
amelioratesγ-secretaseactivityby1.65-fold(P = .02,N = 3)
(Figures 3(d) and 3(e)). These data are consistent with those
obtained with phenanthroline, and suggest that adding Ca2+
and Mg2+metal ions facilitate γ-secretase cleavage of APP
substrate.4 International Journal of Alzheimer’s Disease
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Figure 1: Characterization of γ-secretase in vitro assay with guinea pig brain enzyme. ∼1μg of puriﬁed recombinant C100-3XFLAG was
incubated with 2.75μg of CHAPSO solubilised membranes of guinea pig brain in 20mM HEPES buﬀe r ,p H7 . 3 ,p l u s3m MC a C l 2,3m M
MgCl2 and 150mM KCl. The reactions were stopped by adding Laemmli buﬀer, boiled, and separated on Tris-Tricine gels. M2 (anti-
FLAG) antibody and WO2 (anti-Aβ 1–16) were used for western blot detection. (a) Production of an AICD fragment in the assay is
inhibited by the γ-secretase inhibitors, L-685,458 and DAPT. (b) Both AICD and Aβ are produced in the reaction and inhibited by L-
685,458. AICD signal increases in a time dependent manner over 20h. Aβ signal is increased at 4h compared to 2h, but decreased at
20h, possibly due to degradation. (Inc, incubation at 37◦C). (c) Positive eﬀect of phospholipids on AICD production in the γ-secretase
assay. PC, phosphatidylcholine; PE, phosphatidylethanolamine. (d) Positive eﬀect of ATP on the γ-secretase assay. ATP was added 1.25mM
concentration. (e) Quantitation of three separate experiments using GeneTools Syngene software shows ∼1.6 fold enhancement of γ-
secretase activity in the presence of 1.25mM ATP. The error bars represent SEM.
3.4. Ca2+ and Mg2+ Facilitate γ-Secretase Activity. To deﬁne
which of Ca2+ and Mg2+ ions were important for γ-secretase
activity, we tested the eﬀect of EGTA that has much greater
aﬃnity for calcium than magnesium. In the reactions carried
out with guinea pig or mouse γ-secretase activity, there
were similar levels of AICD produced in the presence of
EGTA than in the presence of EDTA (Figures 4(a) and 4(b)),
suggesting that Ca2+ions are required for the enhancement
of γ-secretase activity. When, reactions were prepared in the
presence of 2mM EDTA and increasing concentrations of
CaCl2 or MgCl2 were added, both Ca and Mg ions individ-
ually restored AICD production to levels achieved with the
Ca and Mg buﬀer (Figure 4(c)). However, when Mg ions
were absent in the reaction, adding 3mM calcium resulted in
precipitation of the C100 substrate. Therefore, both calcium
and magnesium are required for optimal assay conditions.International Journal of Alzheimer’s Disease 5
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Figure 2: Eﬀect of metalloprotease inhibitors, and metal chelators on γ-secretase. Chelators and inhibitors were added as DMSO solutions
(ﬁnalDMSOconcentration2.5%)totheguineapigbrainγ-secretase/C100-3XFLAGreactions.(a)Representativewesternblotofγ-secretase
assay in the presence of various inhibitors. Phpm, phosphoramidon; Ilmst, ilomastat; Pht, phenanthroline; CQ, clioquinol; γ-inh, L-685,458,
used at 10nM (lane 6) and 100nM (lane 7). (b) Eﬀect of metalloprotease inhibitors on the γ-secretase assay. Activity is expressed as the % of
substrate converted into AICD, as determined from band density analysis with GeneTools software. The error bars represent SEM. Inhibitor
concentrationswereselected asfollows:thiorphan,250nM;phosphoramidon,25μM;ilomastat,250nM;phenanthroline,5mM;clioquinol,
100μM.
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Figure 3: Eﬀect of EDTA and phenanthroline on γ-secretase activity. (a) Guinea pig γ-secretase activity was assayed on C100-3XFLAG in
alternate buﬀer conditions (2mM EDTA or 3mM CaCl2 and 3mM MgCl2). (b) Quantitative analysis of ﬁve separate experiments shows
AICD production in the presence of EDTA was 28% of that produced in the presence of CaCl2,a n dM g C l 2. (c) Quantitative analysis of Aβ40
by sandwich DELFIA shows that Aβ production in the presence of EDTA is lower than in the presence of CaCl2,a n dM g C l 2.( d )γ-Secretase
activity extracted from SH-SY5Y membranes was assayed in buﬀer conditions as indicated. Phenanthroline (Pht) concentration was 5mM.
L-685,458 was 0.5μM. (e) Quantitative analysis of three blots corresponding to assays carried out as in (d) The error bars represent SEM.6 International Journal of Alzheimer’s Disease
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3.5. Calcium and Magnesium Ions Stabilize a High Molecular
Weight γ-Secretase Complex. To determine if calcium and
magnesium ions had an eﬀect on the size and stability of
γ-secretase complexes, SH-SY5Y membrane-extracts diluted
with 20mM HEPES, and 150mM KCl (pH 7.3) to a
CHAPSO concentration of 0.5% were incubated in the
presence of either 2mM EDTA, 2mM MgCl2,o r2 m M
CaCl2, and analyzed by BN-PAGE and western blotting for
PS1 (Figure 5(a)). In HEPES buﬀer, with no added calcium
or magnesium, and in the presence of EDTA or EGTA, PS1
was found mostly associated with a 350kDa complex, and a
minor amount with a 450kDa complex. In the incubations
with Mg2+, with or without ATP, presenilin was found
associated with a ∼450kDa complex and also, in a small
proportion with a 1,000kDa complex. In the presence of
Ca2+, PS1 was found mostly associated with the ∼450kDa
complex. These data suggest that Ca2+ and Mg2+ ions
contribute to stabilization of γ-secretase complexes, possibly
in association with binding partners. Further analysis of PS1
γ-secretase complex sizes by gel ﬁltration on a Superose-
6 column (Figure 5(b)) showed that, in the presence of
Mg2+ ions, most PS1 immunoreactivity is recovered in a
symmetrical peak in fractions corresponding to ∼1,000kDa.
In the presence of EDTA, the peak of PS1 immunoreactivity
was less sharp and broader, suggesting decreased complex
stability.
4. Discussion
Biometal ions and metalloenzymes play an important role
in the metabolism of APP and Aβ, and the pharmaco-
modulation of copper levels in the brain represents a
promising therapeutic approach to treat AD [18]. Little is
known about the eﬀect of metal ions on γ-secretase activity.
We found that the copper-selective chelator, clioquinol did
not signiﬁcantly alter AICD production, suggesting that
copper is not directly involved in γ-secretase cleavage of
the APP substrate. This ﬁnding is consistent with our
previous report that CQ does not alter production of Aβ
in CHO-APP cells [28]. The zinc chelators, thiorphan and
phosphoramidon, and the α-secretase inhibitor, ilomastat,
showed no signiﬁcant eﬀect on the γ-secretase reaction.International Journal of Alzheimer’s Disease 7
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Figure 5: Eﬀect of Ca2+ and Mg2+ o nt h es i z eo fγ-secretase complexes analyzed by BNPAGE and size-exclusion chromatography. 10μg
samples of protein extract from SHSY5Y membranes were incubated with HEPES buﬀer, pH 7.3, with or without additives, as indicated.
EGTA and EDTA concentrations were 2mM. CaCl2 and MgCl2 concentrations were 3mM. (a) The incubations were mixed with BN-PAGE
sample buﬀer and electrophoresed on 3–8% Tris-acetate gels. Proteins were transferred to PVDF membrane and the blot probed with anti-
PS1 antibody 98/1. (b) SH-SY5Y membranes (200μg per experiment) were extracted with 0.5% CHAPSO in buﬀer containing either 2mM
EDTA or 3mM MgCl2. The samples were chromatographed on superose-6 size-exclusion column and eluted fractions were analysed by
western blotting with PS1 N-terminal antibody 98/1. Western blot signals were quantiﬁed and plotted against fraction numbers.
In contrast, γ-secretase activity was reduced in the presence
of EDTA and phenanthroline. EGTA had an eﬀect compa-
rable to that of EDTA, indicating the possible involvement
of calcium ions in the assay. Adding back calcium or
magnesium to incubations carried out in the presence of
EDTA showed that both enhanced AICD production.
In vitro γ-secretase assays described in the literature
are carried out in alternative conditions, either in buﬀers
containing EDTA [42, 46], or in buﬀers supplemented with
Ca2+ and Mg2+ [39, 40, 43–45]. The γ-secretase assays
based on Aβ detection are usually carried out in the
presenceofEDTA,probablytopreventmetal-dependentself-
aggregationofthepeptidethatwouldinterferewithantibody
capture in immunoassays, whereas the assays based on
western blot detection of AICD have been preferably carried
out in the presence of calcium and magnesium ions. Parallel
incubationsinEDTAbuﬀerandinbuﬀersupplementedwith
CaCl2,a n dM g C l 2, revealed that AICD production was lower
by 70–78% in the presence of EDTA than in the presence of
Ca2+ and Mg2+.A β levels, detected by ELISA (Figure 3(c)),
werealsohigherinthepresenceofCa2+ andMg2+,suggesting
that the same eﬀect of these ions applies to Aβ and AICD
production.
To investigate whether calcium and magnesium ions
inﬂuence the stability of γ-secretase complex, we used
both BN-PAGE analysis and gel ﬁltration. These techniques
have been previously used to demonstrate that γ-secretase
activity associates with high molecular weight complexes
[44, 47]. In the present paper, fractionation of γ-secretase
preparations by BN-PAGE suggested that Ca2+ and Mg2+
ions stabilized association of PS1 with high molecular
weight complexes of 1,000 and 450kDa, compared to ∼
350kDa complexes observed in the presence of EDTA and
EGTA. When incubations with EDTA and without Ca2+ or
Mg2+were treated with a cross-linker prior to BN-PAGE,
the ∼1,000 complex was also detected in these incubations
(data not shown), suggesting that this 1,000kDa form was
normally present but was less stable through electrophoresis
in the absence of Ca2+ and Mg2+ ions, and without cross-
linking. Size-exclusion chromatography also suggested that
Mg2+ ions stabilized HMW γ-secretase complexes. Although
only the four subunits, PS, nicastrin, Aph1, and Pen-2
are required for γ-secretase activity and formation of a
complex of ∼350kDa, many proteins and other molecules
such as phospholipid and ATP have also been shown to
associate with γ-secretase complexes and to modulate their
activity [48]. For instance, a recent paper reports that PION
protein modulates the speciﬁcity of γ-secretase towards APP
[49]. Three-dimensional reconstruction of the γ-secretase
structure from electron micrographs of puriﬁed γ-secretase
has shown the presence of two weak-density lateral regions
[50] and it is tempting to speculate that these could
accommodate metal ions. Magnesium ions form complexes
with ATP and could mediate the interaction between ATP
and presenilin [40]. Alternatively, calcium and magnesium8 International Journal of Alzheimer’s Disease
may play an accessory role by ordering membrane phos-
pholipids. Indeed, it has been reported that substituting
EDTA-containing buﬀer for a buﬀer supplemented with
calcium and magnesium help stabilize and isolate lipid
rafts [51]. γ-Secretase components associate with lipid rafts,
cholesterol-rich membrane regions where high γ-secretase-
speciﬁc activity has been detected [52, 53]. Furthermore,
experimental evidence indicates that lipids are important
for γ-secretase activity [44]. Therefore, calcium and mag-
nesium may facilitate movement of membrane domains
and substrate access to the γ-secretase active site. Structural
analysis by solid-state NMR and electron microscopy has
demonstrated that cations modulate phospholipid bicelle
size and that MgCl2 and CaCl2 stabilize large diameter
(500 ˚ A) bicelle discs [54]. Thus, the increase in molecular
mass of γ-secretase that was observed when adding divalent
cations may be consistent with the association of a larger
number of detergent and phospholipid molecules with the
γ-secretase complex.
Considering that Aβ has been shown to form mem-
brane pores and disrupt neuronal calcium homeostasis by
increasing Ca2+ inﬂux [55], elevated Aβ could contribute to
increased intraneuronal [Ca2+] that might in turn increase
γ-secretase activity and Aβ production. Thus, it will be
important to clarify how calcium and magnesium tune γ-
secretase activity as this may have potential implications in
AD pathogenesis.
5. Conclusions
Our study indicates that copper and zinc chelators have
no direct eﬀect on γ-secretase activity in vitro. It also
demonstrates that chelators of broad speciﬁcity decrease
cleavage of APP C100 substrate. Furthermore, it shows
that Ca2+ and Mg2+ ions facilitate AICD production and
contribute to stabilizing HMW γ-secretase complexes. This
ﬁnding suggests that Ca2+ and Mg2 mediate molecular
associations that modulate γ-secretase activity.
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